Multivalency

The hallmark of antibodies used for optimization of tumor targeting by design

Sergey M. Deyev, Ekaterina N. Lebedenko

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

High-precision tumor targeting with conventional therapeutics is based on the concept of the ideal drug as a "magic bullet"; this became possible after techniques were developed for production of monoclonal antibodies (mAbs). Innovative DNA technologies have revolutionized this area and enhanced clinical efficiency of mAbs. The experience of applying small-size recombinant antibodies (monovalent binding fragments and their derivatives) to cancer targeting showed that even high-affinity monovalent interactions provide fast blood clearance but only modest retention time on the target antigen. Conversion of recombinant antibodies into multivalent format increases their functional affinity, decreases dissociation rates for cell-surface and optimizes biodistribution. In addition, it allows the creation of bispecific antibody molecules that can target two different antigens simultaneously and do not exist in nature. Different multimerization strategies used now in antibody engineering make it possible to optimize biodistribution and tumor targeting of recombinant antibody constructs for cancer diagnostics and therapy.

Original languageEnglish
Pages (from-to)904-918
Number of pages15
JournalBioEssays
Volume30
Issue number9
DOIs
Publication statusPublished - Sep 2008
Externally publishedYes

Fingerprint

Tumors
Antibodies
Neoplasms
Monoclonal Antibodies
Bispecific Antibodies
Antigens
Magic
Blood
Technology
Derivatives
Molecules
DNA
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Multivalency : The hallmark of antibodies used for optimization of tumor targeting by design. / Deyev, Sergey M.; Lebedenko, Ekaterina N.

In: BioEssays, Vol. 30, No. 9, 09.2008, p. 904-918.

Research output: Contribution to journalArticle

@article{46f186e849d746c985c1e8bfa4f9f3d5,
title = "Multivalency: The hallmark of antibodies used for optimization of tumor targeting by design",
abstract = "High-precision tumor targeting with conventional therapeutics is based on the concept of the ideal drug as a {"}magic bullet{"}; this became possible after techniques were developed for production of monoclonal antibodies (mAbs). Innovative DNA technologies have revolutionized this area and enhanced clinical efficiency of mAbs. The experience of applying small-size recombinant antibodies (monovalent binding fragments and their derivatives) to cancer targeting showed that even high-affinity monovalent interactions provide fast blood clearance but only modest retention time on the target antigen. Conversion of recombinant antibodies into multivalent format increases their functional affinity, decreases dissociation rates for cell-surface and optimizes biodistribution. In addition, it allows the creation of bispecific antibody molecules that can target two different antigens simultaneously and do not exist in nature. Different multimerization strategies used now in antibody engineering make it possible to optimize biodistribution and tumor targeting of recombinant antibody constructs for cancer diagnostics and therapy.",
author = "Deyev, {Sergey M.} and Lebedenko, {Ekaterina N.}",
year = "2008",
month = "9",
doi = "10.1002/bies.20805",
language = "English",
volume = "30",
pages = "904--918",
journal = "BioEssays",
issn = "0265-9247",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Multivalency

T2 - The hallmark of antibodies used for optimization of tumor targeting by design

AU - Deyev, Sergey M.

AU - Lebedenko, Ekaterina N.

PY - 2008/9

Y1 - 2008/9

N2 - High-precision tumor targeting with conventional therapeutics is based on the concept of the ideal drug as a "magic bullet"; this became possible after techniques were developed for production of monoclonal antibodies (mAbs). Innovative DNA technologies have revolutionized this area and enhanced clinical efficiency of mAbs. The experience of applying small-size recombinant antibodies (monovalent binding fragments and their derivatives) to cancer targeting showed that even high-affinity monovalent interactions provide fast blood clearance but only modest retention time on the target antigen. Conversion of recombinant antibodies into multivalent format increases their functional affinity, decreases dissociation rates for cell-surface and optimizes biodistribution. In addition, it allows the creation of bispecific antibody molecules that can target two different antigens simultaneously and do not exist in nature. Different multimerization strategies used now in antibody engineering make it possible to optimize biodistribution and tumor targeting of recombinant antibody constructs for cancer diagnostics and therapy.

AB - High-precision tumor targeting with conventional therapeutics is based on the concept of the ideal drug as a "magic bullet"; this became possible after techniques were developed for production of monoclonal antibodies (mAbs). Innovative DNA technologies have revolutionized this area and enhanced clinical efficiency of mAbs. The experience of applying small-size recombinant antibodies (monovalent binding fragments and their derivatives) to cancer targeting showed that even high-affinity monovalent interactions provide fast blood clearance but only modest retention time on the target antigen. Conversion of recombinant antibodies into multivalent format increases their functional affinity, decreases dissociation rates for cell-surface and optimizes biodistribution. In addition, it allows the creation of bispecific antibody molecules that can target two different antigens simultaneously and do not exist in nature. Different multimerization strategies used now in antibody engineering make it possible to optimize biodistribution and tumor targeting of recombinant antibody constructs for cancer diagnostics and therapy.

UR - http://www.scopus.com/inward/record.url?scp=50249135564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50249135564&partnerID=8YFLogxK

U2 - 10.1002/bies.20805

DO - 10.1002/bies.20805

M3 - Article

VL - 30

SP - 904

EP - 918

JO - BioEssays

JF - BioEssays

SN - 0265-9247

IS - 9

ER -